Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease
Retrieved on:
Wednesday, February 8, 2023
CET, Cohort study, Galapagos NV, Disease, RA, JAK1, Safety, MD, Filgotinib, Axial spondyloarthritis, Euronext, UZ Leuven, UC1, University of Leuven, University, Patient, UC, Crohn's disease, Week, Maintenance, Marketing, Research, Doctor of Philosophy, Pharmaceutical industry, Immunology, Galápagos Islands, Cohort
Induction Cohort A included biologic-naïve (54%) and biologic-experienced (46%) patients; induction Cohort B included biologic-experienced patients.
Key Points:
- Induction Cohort A included biologic-naïve (54%) and biologic-experienced (46%) patients; induction Cohort B included biologic-experienced patients.
- In total, 33% of patients in Cohort A and 52% of patients in Cohort B had failed treatment with 3 or more biologic drugs.
- Both induction cohorts of the study failed to meet the co-primary endpoints of clinical remission and endoscopic response for filgotinib, 100mg and 200mg once daily.
- We are grateful to the patients and all medical professionals who participated in this trial.”